CAMBRIDGE: One of the companies in the race to develop a vaccine to cure the novel and deadly coronavirus has announced that its drug candidate under trial indicated a 94.1% efficacy against COVID-19 and 100% efficacy in severe cases. According to a press release issued Monday, American biotechnology company Moderna said its coronavirus drug candidate — mRNA-1273 — was “generally well tolerated” …
Read More »Moderna’s COVID-19 vaccine indicates 94.1% efficacy against virus, 100% in severe cases
November 30, 2020